ANI Pharma Announces Launch Of Benztropine Mesylate Tablets - Quick Facts

(RTTNews) - ANI Pharmaceuticals, Inc. (ANIP) announced it will immediately launch Benztropine Mesylate Tablets USP 0.5 mg, 1 mg and 2 mg. Benztropine Mesylate Tablets are indicated for use as an adjunct in the therapy of all forms of parkinsonism and may also be useful in the control of extrapyramidal disorders (except tardive dyskinesia) due to neuroleptic drugs.

Arthur Przybyl, ANI's CEO said: "Benztropine is the tenth new commercial product introduction for ANI in 2016. We continue to pursue expansion of our commercial portfolio via internal product development, strategic partnerships, and acquisitions."